A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia

REFERENCES

• World Cancer Research Fund: Food, Nutrition, Physical Activity, and the Prevention of Cancer: a global perspective Washington, DC: World Cancer Research Fund/American Institute for Cancer Research, 2007.
   Google Scholar
• Kristal AR, Till C, Platz EA, Song X, King IB, et al.: Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer epidemiology, Biomarkers & Prevention 20, 638–646, 2011.
   PubMed Web of Science ®Google Scholar
• Giovannucci E: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial. Cancer Causes & Control 22, 1055–1059, 2011.
   PubMed Web of Science ®Google Scholar
• Wei MY and Giovannucci EL: Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. Journal of Oncology 2012, 271063, 2012.
   PubMedGoogle Scholar
• Sies H and Stahl W: Lycopene: antioxidant and biological effects and its bioavailability in the human. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine 218, 121–124, 1998.
   PubMed Web of Science ®Google Scholar
• Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, et al.: Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate. FASEB Journal 19, 272–274, 2005.
   PubMed Web of Science ®Google Scholar
• Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, et al.: Lycopene effects on rat normal prostate and prostate tumor tissue. The Journal of Nutrition 135, 2050S–2052S, 2005.
   PubMed Web of Science ®Google Scholar
• Tang L, Jin T, Zeng X, Wang JS: Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. The Journal of Nutrition 135, 287–290, 2005.
   PubMed Web of Science ®Google Scholar
• Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, et al.: Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 45, 275–282, 2006.
   PubMed Web of Science ®Google Scholar
• Liu X, Allen JD, Arnold JT, and Blackman MR: Lycopene inhibits IGF-I signal transduction and growth in normal prostate epithelial cells by decreasing DHT-modulated IGF-I production in co-cultured reactive stromal cells. Carcinogenesis 29, 816–823, 2008.
   PubMed Web of Science ®Google Scholar
• van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, et al.: Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prevention Research 4, 711–718, 2011.
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, et al.: A working group classification of focal prostate atrophy lesions. The American Journal of Surgical Pathology 30, 1281–1291, 2006.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, et al.: The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54, 1379–1384, 2008.
   PubMed Web of Science ®Google Scholar
• Nonn L, Ananthanarayanan V, and Gann PH: Evidence for field cancerization of the prostate. Prostate 69, 1470–1479, 2009.
   PubMed Web of Science ®Google Scholar
• Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, et al.: Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 192, 1081–1087, 2014.
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, and Gann PH: Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 6, 73, 2006.
   PubMed Web of Science ®Google Scholar
• Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, et al.: Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. The Journal of Nutrition 133, 3356–3360, 2003.
   PubMed Web of Science ®Google Scholar
• Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, et al.: Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer prevention research 6, 419–427, 2013.
   PubMed Web of Science ®Google Scholar
• Mohanty NK, Saxena S, Singh UP, Goyal NK, Arora RP: Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urologic Oncology 23, 383–385, 2005.
   PubMed Web of Science ®Google Scholar
• Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, et al.: Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. International Journal of Molecular Sciences 15, 1433–1440, 2014.
   PubMed Web of Science ®Google Scholar
• Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, et al.: Lycopene inhibits disease progression in patients with benign prostate hyperplasia. The Journal of Nutrition 138, 49–53, 2008.
   PubMed Web of Science ®Google Scholar
• Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, et al.: A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer 57, 130–137, 2007.
   PubMed Web of Science ®Google Scholar
• Riso P, Brusamolino A, Martinetti A, and Porrini M: Effect of a tomato drink intervention on insulin-like growth factor (IGF)-1 serum levels in healthy subjects. Nutr Cancer 55, 157–162, 2006.
   PubMed Web of Science ®Google Scholar
• Walfisch S, Walfisch Y, Kirilov E, Linde N, Mnitentag H, et al.: Tomato lycopene extract supplementation decreases insulin-like growth factor-I levels in colon cancer patients. European Journal of Cancer Prevention 16, 298–303, 2007.
   PubMed Web of Science ®Google Scholar
• Graydon R, Gilchrist SE, Young IS, Obermuller-Jevic U, Hasselwander O, et al.: Effect of lycopene supplementation on insulin-like growth factor-1 and insulin-like growth factor binding protein-3: a double-blind, placebo-controlled trial. Eur J Clin Nutr 61, 1196–1200, 2007.
   PubMed Web of Science ®Google Scholar
• Vrieling A, Voskuil DW, Bonfrer JM, Korse CM, van Doorn J, et al.: Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer. The American Journal of Clinical Nutrition 86, 1456–1462, 2007.
   PubMed Web of Science ®Google Scholar
• Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, et al.: Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. Cancer Causes & Control 22, 141–150, 2011.
   PubMed Web of Science ®Google Scholar
• Mucci LA, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, et al.: Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 87, 814–820, 2001.
   PubMed Web of Science ®Google Scholar
• Padmanabhan V, Callas P, Philips G, Trainer TD, and Beatty BG: DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 57, 1057–1062, 2004.
   PubMed Web of Science ®Google Scholar
• Erdamar S, Yang G, Harper JW, Lu X, Kattan MW, et al.: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Modern Pathology 12, 751–755, 1999.
   PubMed Web of Science ®Google Scholar
• Waltregny D, Leav I, Signoretti S, Soung P, Lin D, et al.: Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15, 765–782, 2001.
   PubMed Web of Science ®Google Scholar
• Sinha R and El-Bayoumy K: Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Current Cancer Drug Targets 4, 13–28, 2004.
   PubMed Web of Science ®Google Scholar
• Venkateswaran V, Fleshner NE, and Klotz LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. The Journal of Urology 168, 1578–1582, 2002.
   PubMed Web of Science ®Google Scholar
• Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, et al.: Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 20, 3428–3436, 2001.
   PubMed Web of Science ®Google Scholar
• Venkateswaran V, Klotz LH, Ramani M, Sugar LM, Jacob LE, et al.: A combination of micronutrients is beneficial in reducing the incidence of prostate cancer and increasing survival in the Lady transgenic model. Cancer Prevention Research 2, 473–483, 2009.
   PubMed Web of Science ®Google Scholar
• Palozza P, Colangelo M, Simone R, Catalano A, Boninsegna A, et al.: Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 31, 1813–1821, 2010.
   PubMed Web of Science ®Google Scholar
• Murphy MM, Barraj LM, Herman D, Bi X, Cheatham R, et al.: Phytonutrient intake by adults in the United States in relation to fruit and vegetable consumption. Journal of the Academy of Nutrition and Dietetics 112, 222–229, 2012.
   PubMed Web of Science ®Google Scholar
• Itsiopoulos C, Hodge A, and Kaimakamis M: Can the Mediterranean diet prevent prostate cancer? Molecular Nutrition & Food Research 53, 227–239, 2009.
   PubMed Web of Science ®Google Scholar